Accès à distance ? S'identifier sur le proxy UCLouvain
Outcomes of glycemic control in type 1 diabetic patients switched from basal insulin glargine 100 U/ml to glargine 300 U/ml in real life
Primary tabs
Document type | Article de périodique (Journal article) – Article de recherche |
---|---|
Publication date | 2018 |
Language | Anglais |
Journal information | "Expert Review of Endocrinology & Metabolism" - Vol. 13, no. 3, p. 167-171 (2018) |
Peer reviewed | yes |
Publisher | Tayor & Francis ((United Kingdom) Abingdon) |
issn | 1744-6651 |
e-issn | 1744-8417 |
Publication status | Publié |
Affiliations |
UCL
- (SLuc) Service d'endocrinologie et de nutrition UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition |
Keywords | Type 1 diabetes ; Glargine 100U/ml ; Glargine 300 U/ml ; Glycemic control ; Hypoglycemia ; Insulin doses ; Switch ; Weight |
Links |
- Hirsch Irl B., Insulin Analogues, 10.1056/nejmra040832
- Lavens A, Initiative pour la Promotion de la qualite et de l’Epidemiologie du Diabete sucre (IPQED) – Rapport resultats 2014 – Direction operationnelle Sante Publique et Surveillance (2016)
- Shiramoto M., Eto T., Irie S., Fukuzaki A., Teichert L., Tillner J., Takahashi Y., Koyama M., Dahmen R., Heise T., Becker R. H. A., Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes, 10.1111/dom.12415
- Becker RH, Diabetes Care, 38, 637 (2015)
- Home Philip D., Bergenstal Richard M., Bolli Geremia B., Ziemen Monika, Rojeski Maria, Espinasse Melanie, Riddle Matthew C., New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4), 10.2337/dc15-0249
- Ashwell S. G., Gebbie J., Home P. D., Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart, 10.1111/j.1464-5491.2006.01913.x
- Lepore M., Pampanelli S., Fanelli C., Porcellati F., Bartocci L., Di Vincenzo A., Cordoni C., Costa E., Brunetti P., Bolli G. B., Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro, 10.2337/diabetes.49.12.2142
- Koehler G., Treiber G., Wutte A., Korsatko S., Mader J. K., Semlitsch B., Pieber T. R., Pharmacodynamics of the long-acting insulin analogues detemir and glargine following single-doses and under steady-state conditions in patients with type 1 diabetes, 10.1111/dom.12178
- Gradišer Marina, Berković Maja Cigrovski, Bilić-Ćurčić Ines, Changes in HbA1c and hypoglycemic episodes in type 1 diabetes patients after switching to insulin glargine U300: Pilot study, 10.1016/j.diabres.2017.03.036
- Goldman Jennifer, Kapitza Christoph, Pettus Jeremy, Heise Tim, Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice, 10.1080/03007995.2017.1335192
- Bolli G. B., Riddle M. C., Bergenstal R. M., Ziemen M., Sestakauskas K., Goyeau H., Home P. D., , New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3), 10.1111/dom.12438
- Ritzel R., Roussel R., Bolli G. B., Vinet L., Brulle-Wohlhueter C., Glezer S., Yki-Järvinen H., Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes, 10.1111/dom.12485
Bibliographic reference | Oriot, Philippe ; Jérémie, Wawrzyniak ; Buysschaert, Martin. Outcomes of glycemic control in type 1 diabetic patients switched from basal insulin glargine 100 U/ml to glargine 300 U/ml in real life. In: Expert Review of Endocrinology & Metabolism, Vol. 13, no. 3, p. 167-171 (2018) |
---|---|
Permanent URL | http://hdl.handle.net/2078.1/215753 |